Pulmonary hypertension in thoracic surgical patients

Current Opinion in Anaesthesiology

Volumn 23, Issue 1, 2010, Pages 25-33

  Ross, Alan F ^a   Ueda, Kenichi ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Bosentan; Epoprostenol; Inhaled pulmonary vasodilators; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VERAPAMIL;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; BLEEDING; BLURRED VISION; CLINICAL ASSESSMENT; COUGHING; DIARRHEA; DOPPLER ECHOCARDIOGRAPHY; DYSPEPSIA; EDEMA; EPISTAXIS; ERYTHEMA; FLUSHING; HEADACHE; HEART CATHETERIZATION; HUMAN; INJECTION SITE PAIN; JAW PAIN; LEG EDEMA; LIVER TOXICITY; MALE INFERTILITY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NOSE CONGESTION; PAIN; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; REVIEW; SIDE EFFECT; SYNCOPE; TACHYCARDIA; TERATOGENICITY; TESTIS ATROPHY; THORAX SURGERY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; VISUAL DISORDER;

ANESTHESIA, INHALATION; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PURINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; SULFONES; THORACIC SURGICAL PROCEDURES; VASODILATOR AGENTS;

EID: 75149113170     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328334cb59     Document Type: Review

References (84)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACC/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. Circulation 2009; 119:2250-2294.
2. Humbert M, McLaughlin VV. The 4th world symposium on pulmonary hypertension. J Am Coll Cardiol 2009; 54:S1-S2.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54.
4. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:1527-1538.
5. Badesch DB, Champion HC, Sanchez MAG, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55-S66.
6. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54:S85-S96.
7. McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol 2004; 29:575-634.
8. Beghetti M, Galiè N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53:733-740.
9. Khush KK, Tasissa G, Butler J, et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE) database. Am Heart J 2009; 157:1026-1034.
10. Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113:237-240.
11. Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest 2008; 134:808-814.
12. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J COPD 2008; 3:55-70.
13. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76:1457-1464.
14. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54:S67-S77.
15. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. Ann Int Med 1987; 107:216-223.
16. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:14S-34S.
17. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:40S-47S.
18. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007; 96:527-541.
19. Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovasc Interv 2008; 71:205-213.
20. Brecker SJD, Gibbs JSR, Fox KM, et al. Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. Br Heart J 1994; 72:384-389.
21. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52:1683-1692.
22. D'Alonzo GE, Barst RJ, Ayers SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
23. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004; 25:2243-2278.
24. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143:282-292.
25. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351:1655-1665.
26. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903.
27. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301.
28. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917-1928.
29. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258:199-215.
30. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29:2134-2153. (Pubitemid 350138566)
31. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
32. Cheng JWM. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008; 30:825-833.
33. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006; 2:411-422.
34. Simmoneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521-530.
35. Ghofrani HA, WilkinsMW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118:1195-1201.
36. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482-1489.
37. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30:394-403.
38. Rhodes CJ, Davidson A, Gibbs JSR, et al. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121:69-88.
39. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J 2008; 32:503-512.
40. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53:1211-1218.
41. Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2008; 294:H801-H809.
42. Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in eisenmenger sydrome. J Am Coll Cardiol 1999; 33:222-227.
43. RamakrishnaG, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45:1691-1699.
44. Lai H-C, Lai H-C, Wang K-Y, et al. Severe pulmonary hypertension complicates postoperative outcome of noncardiac surgery. Br J Anaesth 2007; 99:184-190.
45. Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of videoassisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007; 83:1140-1145.
46. Heller AR, Litz RJ, Koch T. A fine balance: one-lung ventilation in a patient with Eisenmenger syndrome. Br J Anaesth 2004; 92:587-590.
47. Ito R, Shime N, Yamazaki Y, et al. Anesthetic experience in a case of an adolescent with severe pulmonary hypertension associated with ventricular septal defect. Masui 2004; 53:309-312.
48. Hasegawa S, Isowa N, Bando T, Wada H. The inadvisability of thoracoscopic lung biopsy on patients with pulmonary hypertension. Chest 2002; 122:1067-1068.
49. Armstrong P. Thoracic epidural anaesthesia and primary pulmonary hypertension. Anaesthesia 1992; 47:496-499.
50. Cheng DCH, Edelist G. Isoflurane and primary pulmonary hypertension. Anaesthesia 1988; 43:22-24.
51. Höhn L, Schweizer A, Morel DR, et al. Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology 1999; 91:1943-1945.
52. Rex S, Missant C, Segers P, Wouters PF. Thoracic epidural anesthesia impairs the hemodynamic response to acute pulmonary hypertension by deteriorating right ventricular-pulmonary arterial coupling. Crit Care Med 2007; 35:222-229.
53. Hemnes AR, Champion HC. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract 2008; 62:11-19.
54. van Wolferen SA, Marcus JT, Westerhof N, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 2008; 29:120-127.
55. Murray PA, Vatner SF. Reduction of maximal coronary vasodilator capacity in conscious dogs with severe right ventricular hypertrophy. Circ Res 1981; 48:25-33.
56. Hirsch LJ, Rooney MW, Wat SS, et al. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1991; 100:796-801.
57. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. Anaesthesia 2002; 57:9-14.
58. Acosta F, Sansano T, Palenciano CG, et al. Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. Transplant Proc 2005; 37:3869-3870.
59. Leather HA, Segers P, Berends N, et al. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548-2552.
60. Hüter L, Schwarzkopf K, Preussler NP, et al. Effects of arginine vasopressin on oxygenation and haemodynamics during one-lung ventilation in an animal model. Anaesth Intensive Care 2008; 36:162-166.
61. Rocca GD, Passariello M, Coccia C, et al. Inhaled nitric oxide administration during one-lung ventilation in patients undergoing thoracic surgery. J Cardiothorac Vasc Anesth 2001; 15:218-223.
62. Rocca GD, Coccia C, Pompei L, et al. Hemodynamic and oxygenation changes of combined therapy with inhaled nirtic oxide and inhaled aerosolized prostacyclin. J Cardiothorac Vasc Anesth 2001; 15:224-227.
63. Wilson WC, Kapelanski DP, Benumof L, et al. Inhaled nitric oxide (40ppm) during one-lung ventilation, in the lateral decubitus position, does not decrease pulmonary vascular resistance or improve oxygenation in normal patients. J Cardiothorac Vasc Anesth 1997; 11:172-176.
64. Flondor M, Merkel M, Hofstetter C, et al. The effect of inhaled nitric oxide and inhaled iloprost on hypoxaemia in a patient with pulmonary hypertension after pulmonary thrombarterectomy. Anaesthesia 2006; 61:1200-1203.
65. Rusca M, Oddo M, Schaller M-D, Liaudet L. Carboxyhemoglobin formation as an unexpected side effect of inhaled nitric oxide therapy in severe acute respiratory distress syndrome. Crit Care Med 2004; 32:2537-2539.
66. Oishi P, Grobe A, Benavidez E, et al. Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: a role for superoxide and peroxynitrite in the intact lamb. Am J Physiol Lung Cell Mol Physiol 2006; 290:L359-L366.
67. Bund M, Henzler D, Walz R, et al. Aerosolized and intravenous prostacyclin during one-lung ventilation. Hemodynamic and pulmonary effects. (German) Anaesthesist 2004; 53:612-620.
68. Haraldsson A ° , Kieler-Jensen N, Ricksten S-E. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001; 93:1439-1445.
69. Augoustides JG, Culp K, Smith S. Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology 2004; 100:1023-1025.
70. Haraldsson A ° , Kieler-Jensen N, Wadenvik H, Ricksten S-E. Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med 2000; 26:188-194. (Pubitemid 30186593)
71. Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005; 28:882-888.
72. Yin N, Kaestle S, Yin J, et al. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 2009; 37:980-986.
73. Rex S, Missant C, Claus P, et al. Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit Care 2008; 12:R113-R125.
74. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008; 22:406-413.
75. Sandifer BL, Brigham KL, Lawrence EC, et al. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol 2005; 99:2363-2368.
76. Rocca GD, Coccia C, Pompei L, et al. Inhaled areosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol 2008; 74:627-633.
77. Yurtseven N, Karaca P, Kaplan M, et al. Effect of nitroglycerin inhalation on patients with pulmonary hypertension undergoing mitral valve replacement surgery. Anesthesiology 2003; 99:855-858.
78. Yurtseven N, Karaca P, Uysal G, et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg 2006; 12:319-323.
79. Schreiber MD, Dixit R, Rudinsky B, et al. Direct comparison of the effects of nebulized nitroprusside versus inhaled nitric oxide on pulmonary and systemic hemodynamics during hypoxia-induced pulmonary hypertension in piglets. Crit Care Med 2002; 30:2560-2565.
80. Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26:462-468.
81. Hentschel T, Yin N, Riad A, et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 2007; 106:124-131.
82. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104:424-428.
83. Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg 2008; 107:1026-1040.
84. Daly DJ, Myles PS. Update on the role of paravertebral blocks for thoracic surgery: are they worth it? Curr Opin Anaesthesiol 2009; 22:38-43.